

BSN Journal Secretary's Report 2025

The Journal of Neuroendocrinology is performing extremely well, with the excellent rise in JNE's impact factor, from 3.3 to 4.1, and its move up the ranks to above Endocrinology (3.3), Journal of Endocrinology (3.9), Neuroendocrinology (2.9), and Journal of Neuroscience (4.0). It now sits in quartile 1 of the Neuroscience Category (76/314) and at the top of quartile 2 in the Endocrinology and Metabolism Category (55/191). This is a result of a series of strategic decisions that have been made over the past 5-8 years: publicising the importance of being a society-based journal; supporting a range of international meetings; providing careerbuilding opportunities for early career researchers; and establishing a clinical and translational strand to complement the existing strengths in fundamental and mechanistic neuroendocrinology.

The publishers (Wiley) have reported that the circulation of the journal has remained stable, among a changing environment where the vast majority of sales have now moved from classical subsciptions to transformational. While circulation has been stable, readership of the journal is trending upwards, and this is a trend that is continuing into 2025 (up 7.42% YTD).

Over the past 4 years, there has been a decreasing trend in the number of articles published, but this seems to be turning around in 2025, with a 40% increase in submissions this year to date, associated with a 50% increase in articles published (year to date). This is very promising for a sustainable increase in number of articles published – critically important as the move to open access publishing continues to evolve. Overall, the acceptance rate is down, at around 36% in 2025. This should be sustaining the quality of the articles, despite the increased submission rate. With the increasing number of publications, however, we also need to see the citations increasing, or else the impact factor will suffer. At present, citation numbers for the year to date are similar to last year, hopefully meaning we can maintain the current improvement in the impact factor.

It is important to continue to highlight that JNE is an international journal, with both submissions and readership coming from all over the world. The UK represents less than 10% of submissions and readership activity for the journal. One of the strategic goals of the journal has been to expand the geographical reach of the journal and attract content from new areas. For example, in 2024 editors Mike Lehman and Bob Goodman attended a training workshop in India, and there has been increased activity in Latin America thanks to our ongoing collaboration with PANS. The addition of the Translational and Clinical Neuroendocrinology strand (Editor-in-Chief Wouter de Herder) has been extremely successful, particularly in bringing across the ENETS Guidance reports which have dominated our "most viewed articles" list.

Wiley undertake both targeted and untargeted marketing, but it is not clear what sort of impact this has on submissions or engagement. Most engagement likely comes from scientific interactions, such as meeting sponsorship and recognition of society membership. JNE generated 2,127 "Altmetric" mentions in 2024, with the bulk of these (927) on "X". However, this Altmetric attention is heavily dominated by a few articles that attract a lot of

attention in the popular media. For example, in 2024, over half of our Altmetric attention could be attributed to 2 articles, one on gender and sexual orientation, and one on gluten effects in the hypothalamus.

Wiley have had 3 focus areas over the past few years:

- Embracing AI to enhance publishing process
 - o Tools to check for papermill and other aspects of publishing integrity
 - o Potential for growth opportunities for targeted dissemination
 - o Improve productivity through the processing pipeline
- Growing number of transformational agreements
 - o 103 agreements, covering 3000 institutions
 - Enabling increased open access publishing
- Inroducing Research Exchange a "harmonized submission screening and peer review platform". This will enable a move to "continuous publishing", with "EarlyView becoming redundent.

The impact that these initiatives have on JNE success will be seen over the next few years. Senior editors are involved in the discussion of the pros and cons of continuous publication. A decision will be made soon about moving to continuous publication.

Overall, this has been a very positive year for the journal. It has out-performed similar journals in the field, and positioned itself to be a leading place for people to submit their work. With ongoing support from Society members, we can expect to see this success continue. I'd like to congratulate the Editors and their Editorial staff on the success of the strategic plan for the journal.